Next Century Growth Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Next Century Growth Investors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-126	Closed	-$14K	–	200
2016 Q2	$14K	Sell	126 -13,581	-99%	-$1.93M	﹤0.01%	175
2016 Q1	$1.91M	Buy	13,707 +76	+0.6%	+$11.2K	0.09%	149
2015 Q4	$2.6M	Sell	13,631 -6,622	-33%	-$1.16M	0.11%	152
2015 Q3	$3.17M	Sell	20,253 -183	-0.9%	-$33.4K	0.13%	140
2015 Q2	$3.69M	Sell	20,436 -530	-3%	-$91.5K	0.13%	166
2015 Q1	$3.63M	Sell	20,966 -510	-2%	-$92.3K	0.13%	164
2014 Q4	$3.97M	Sell	21,476 -4,278	-17%	-$793K	0.14%	153
2014 Q3	$4.27M	Sell	25,754 -8,052	-24%	-$1.32M	0.15%	145
2014 Q2	$5.28M	Buy	33,806 +198	+0.6%	+$31.3K	0.17%	140
2014 Q1	$5.11M	Buy	33,608 +1,736	+5%	+$276K	0.15%	149
2013 Q4	$4.24M	Buy	31,872 +248	+0.8%	+$29.8K	0.12%	161
2013 Q3	$3.67M	Sell	31,624 -427	-1%	-$46.8K	0.11%	155
2013 Q2	$2.96M	Buy	+32,051	New	+$3.09M	0.09%	152

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Next Century Growth Investors's ALXN Position: Q3 2016 in Review

Next Century Growth Investors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 126 shares — an estimated $14K sold.

Next Century Growth Investors first reported a position in ALXN in Q2 2013 and held it in 13 quarters. The position peaked at $5.28M in Q2 2014. 518 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

Next Century Growth Investors reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Next Century Growth Investors sold 126 Alexion Pharmaceuticals shares in Q3 2016, an estimated $14K.
Next Century Growth Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Next Century Growth Investors's Alexion Pharmaceuticals position peaked at $5.28M in Q2 2014.
518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Next Century Growth Investors's 13F filing for Q3 2016, filed 14 Nov 2016.